Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).
Naveen S. Basappa, Daniel Yick Chin Heng(University of Calgary), Marie Vanhuyse, M. Neil Reaume(The University of Melbourne), Austin Kalirai(University of Alberta), Hao‐Wen Sim(The University of Sydney), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Sebastién J. Hotte(Juravinski Cancer Centre), Éric Lévesque(Medical Council of Canada), Scott North, Denis Soulières(Centre Hospitalier de l’Université de Montréal), Piotr Czaykowski(CancerCare Manitoba), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Haocheng Li(University of Calgary), Christina M. Canil(University of Ottawa), Georg A. Bjarnason(Sunnybrook Health Science Centre), Anil Kapoor(People’s University)
Cited by 6
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
|The Lancet Oncology|2012|1.4k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798